Intas Pharma Acquired Teva’s UK, Ireland Generics Businesses

In developed markets, as pharmaceutical enterprises grapple with pricing pressures and expiring patents, they have started expecting a lot from emerging markets. Even large emerging pharmaceutical markets are expected to grow more powerfully than developed markets in the near term. The share of profits and revenues subsidized by emerging countries is lesser in pharma than in other global industries. Also, major multinationals have yet to beat these countries’ vast emerging middle classes.

Generic companies looking to surge market share, scale, revenue, and competitive advantage have also been active with Mergers and Acquisitions (M&A). They have retorted to various stumbling block through strenuous M&A activity and partnerships, compelled by the need for reverse integration, speedy geographic expansion, emerging markets, active pharmaceutical ingredients, and destructive portfolio that are built in specialty, niche, and biologics products.

One such recent M&A activity among largest overseas acquisitions by Intas Pharmaceuticals, an Ahmedabad-based India pharmaceutical company acquiring the generics business of Actavis in the UK and Ireland from global generics giant Teva happened for an enterprise value of £600 million (Rs 5,100 crore). In 2016, it is the biggest outbound M&A transaction in the pharma space so far.

At a usual universal consumer goods firm, emerging markets account for a share of around 1.5 to 3 times greater than at a typical multinational pharma enterprise. These kind of figures indicate that emerging markets are still developing and proffer noteworthy opportunities for further development. However, such optimism that multinational pharma companies face in emerging markets must be tempered by getting aware of the volatility and challenges. Numerous factors that are fueling rapid growth in the global generic pharmaceutical industry include growing middle class in emerging markets, rapidly increasing healthcare expenditures of governments’ and payers’ and a longer life expectancy of living long-life. A great number of patent expiration of innovator drugs has also boosted the growth of the generic industries.

The UK market being a highly competitive one, the UK market is acquiring established brands for increasing market penetration and this strategy is serving Indian generic companies as well. In Europe, UK is one of the top two generics market. While there is robust potential for growing in the market and a highly competitive market. For any Indian generic drug maker who is eyeing to upsurge its UK market share, makes sense for them to go for well entrenched brands in the market.

The rapid growth of the generic industry has faced a number of challenges, such as heavy competition, including from authorized generics in the United States, introduction of lowest-price tendering and Government-mandated price cuts in certain European markets, all have contributed to diminishing prices and ever decreasing margins. These challenges faced by generic companies were tackled by, diversifying their product portfolios, achieving economies of scale, becoming vertically integrated across the manufacturing process, and expanding their geographic presence into emerging markets.

Moreover, in order to weather the storm, many generic companies have relied on M&A rather than organic growth. Looking forward, it is believed that emerging markets will continue to proffer smart opportunities for growth, but pharma firms will need to sail across the intricacies of individual markets while tailoring commercial models in an approach to their specific needs.

To Know About Latest Report Click Here


Global Hemophilia Therapeutics Market: Asia Pacific to Register Robust Growth during 2015-2021

Hemophilia is an inherited disorder in which the lack of sufficient blood clotting factor inhibits clotting of blood normally. The clotting factor consists of proteins that wok with platelets to help the blood clot. According to the U.S. Centers for Disease Control and Prevention, hemophilia occurs in around one in 5,000 male births in the U.S. alone. Every year, 400 babies are born with hemophilia in the country. The growing prevalence of hemophilia has led to the growth of the global hemophilia therapeutics market. Technological advancements in hemophilia drug innovation, along with the development of novel coagulating factors, are anticipated to contribute towards the growth of the market in the near future.

Read Full Report:

Continue reading “Global Hemophilia Therapeutics Market: Asia Pacific to Register Robust Growth during 2015-2021”

Global Opioids Market Benefits from Increasing Endorsement of Palliative Medicine

The global opioids market was worth US$33.9 bn in 2014, says Persistence Market Research. North America contributed the largest revenue to the market – accounting for 65% of the total – followed by Europe, which contributed almost 20% of the revenue in 2014. In North America, opioids are widely used for palliative care, which is the foremost reason for the large revenue contribution of the region. Easy availability of a large range of opioids over the counter not regulated for their abusive consumption and unregulated prescriptions by physicians are contributing to this.

Read Full Report:

Continue reading “Global Opioids Market Benefits from Increasing Endorsement of Palliative Medicine”

Increasing Prevalence of Dermatophytic Onychomycosis among Geriatric Population Drives Global Dermatophytic Onychomycosis Therapeutics Market

While it may not be a life-threatening condition, dermatophytic onychomycosis constitutes a crucial public health concern due to its high prevalence. Dermatophytic onychomycosis is more common among people belonging to the age group of 60-65 years. Onychomycosis caused by dermatophytes is a fungal infection of nails, which makes them look thickened, opaque, white, and brittle. The global market for dermatophytic onychomycosis therapeutics mainly consists of drugs administered to treat the condition.

Read Full Report:

Continue reading “Increasing Prevalence of Dermatophytic Onychomycosis among Geriatric Population Drives Global Dermatophytic Onychomycosis Therapeutics Market”

Global Market for Treatment for Syndromes of Dementia and Movement Disorders Driven by Rising Investments

Ailments related to brain are considered the most complex and toughest to treat. One step ahead on this road of complexity is the human knowledge about a number of neurodegenerative diseases. Successful management of neurodegenerative diseases such as dementia, which is a group chronic or persistent mental disorders and is marked by a progressive decline in the intellectual functioning, personality changes, impaired reasoning, and memory disorders in patients, is one of the biggest challenges before the medical community today.

What makes the task of managing such neurodegenerative diseases tough is the fact that there are currently no or very few effective therapies available for curing them. The precise cause of dementia is still unknown and the reasons behind the many crucial aspects of dementia, such as how the loss of neurons and dysfunctional neural signaling translates into disabilities such as movement disorder or how mind-body co-ordination is altered in neurodegenerative diseases are unclear even after the several years of research.

Read Full Report:

Continue reading “Global Market for Treatment for Syndromes of Dementia and Movement Disorders Driven by Rising Investments”